NCT05655325 Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity
| NCT ID | NCT05655325 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Mild Cognitive Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 144 participants |
| Start Date | 2024-06-18 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 144 participants in total. It began in 2024-06-18 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see if 6 months of home-based walking will improve memory, and brain structure and function, compared to health education in older adults that have chronic kidney disease and mild cognitive impairment.
Eligibility Criteria
Inclusion Criteria: * • Diagnosed stage 3-4 chronic kidney disease (CKD, estimated glomerular filtration rate (eGFR) \<60 to 20 ml/min); * \>55 yrs of age * Mild cognitive impairment (18-26 on the MOCA) * ability to undergo an MR * no history of major head trauma (No head trauma/concussion with loss of consciousness) * Speaks, reads, writes English Exclusion Criteria: * • Diagnosed Dementia or a Clinical Dementia Rating Scale score of \<2, or a MOCA of \<18 * Participating in a supervised exercise program with intent to increase fitness levels 3 days/week, * Requires assistive ambulation * Limited exercise capacity due to claudication; unstable angina, severe arthritis, extreme dyspnea on exertion, unstable coronary artery disease * Class III-IV heart failure * History of uncontrolled sustained arrhythmias, severe/symptomatic aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy, severe pulmonary hypertension, active myocarditis/pericarditis, thrombophlebitis, and recent systemic/pulmonary embolus * Resting systolic BP \>200 mmHg or resting diastolic BP \>110 mmHg * Any unforeseen illness or disability that would preclude cognitive testing or exercise training * One or more contraindication for MRI; cardiac pacemaker, aneurysm clip, cochlear implants, shrapnel, history of metal fragments in eyes, neurostimulators, diagnosed claustrophobia (MRI only) * Any self-reported major psychiatric disorders requiring medical therapy (e.g. schizophrenia, bipolar disorder). * Self-reported new diagnosis of clinical depression within 3 months of enrollment or unstable clinical depression requiring medication adjustment within 3 months of enrollment
Contact & Investigator
Ulf G Bronas, PhD
STUDY CHAIR
Columbia University
Frequently Asked Questions
Who can join the NCT05655325 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05655325 currently recruiting?
Yes, NCT05655325 is actively recruiting participants. Contact the research team at ub2154@cumc.columbia.edu for enrollment information.
Where is the NCT05655325 trial being conducted?
This trial is being conducted at Washington D.C., United States, New York, United States.
Who is sponsoring the NCT05655325 clinical trial?
NCT05655325 is sponsored by Columbia University. The principal investigator is Ulf G Bronas, PhD at Columbia University. The trial plans to enroll 144 participants.